Houston
-
INVEST Pitch Perfect Spotlight: How Prana Thoracic Can Help Treat Lung Cancer Sooner
Prana Thoracic, a startup focused on earlier detection and intervention for lung cancer, recently won the medical devices track of the MedCity News INVEST Pitch Perfect contest. The company is developing a minimally invasive electrosurgical device to help thoracic surgeons better excise smaller and intermediate-size lung nodules.
-
What Healthcare Insights Can We Gain from Space Exploration?
In an interview, the deputy director and chief innovation officer of Translational Research Institute for Space Health, headquartered at Baylor College of Medicine, described some of the group’s work, adapting known tech for space applications and using space-based insights to improve healthcare at home.
-
Streamline the Process for Consent Collection and Management
Join us on April 16th and hear executives from DocuSign and Velatura discuss how their partnership modernizes and facilitates the efficient and secure completion of the patient consent form.
-
MD Anderson researchers find mechanisms behind CAR-T cells’ efficacy, toxicity
The findings may make it possible to identify a subset of patients who experience poorer outcomes or more serious side effects, especially neurotoxicity.
-
Early data show CAR-NK cells’ potential to overcome CAR-T toxicity – and Takeda is interested
Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients’ own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.
-
MD Anderson oncologist Stephen Hahn confirmed as FDA commissioner
The Senate voted 72-18 Thursday to confirm Hahn, a radiation oncologist and chief medical executive at The University of Texas MD Anderson Cancer Center.
-
Trump nominates MD Anderson oncologist as next FDA chief
HHS announced that it had nominated Dr. Stephen Hahn as the next FDA commissioner. Acting Commissioner Ned Sharpless will return to the National Cancer Institute, while HHS official Brett Giroir will temporarily step in pending Hahn’s confirmation.
-
Report: Trump set to tap MD Anderson’s Hahn as FDA commissioner next week
Dr. Stephen Hahn, a radiation oncologist and MD Anderson’s chief medical executive, has reportedly been in the running since September to succeed former FDA Commissioner Scott Gottlieb and current acting commissioner Ned Sharpless.
-
Report: Trump on track to nominate MD Anderson’s Dr. Stephen Hahn as FDA commissioner
BioCentury reported that the the nomination of radiation oncologist Dr. Stephen Hahn, who had been under consideration, would follow an FBI background check. Acting Commissioner Ned Sharpless and Brett Giroir, an assistant HHS secretary, had also reportedly been in the running.
-
Report: MD Anderson oncologist is under consideration for FDA post
Trump is reportedly considering Dr. Stephen Hahn to head the FDA. Others reportedly under consideration include acting Commissioner Ned Sharpless and HHS assistant secretary Brett Giroir.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Exclusive: Director of TMC Venture Fund has been let go
Juliana Garaizar’s removal marks the second time in the past 12 months that TMC’s leadership is making executive changes at the very top of organizations under its umbrella that are dedicated to startup investing and innovation.
-
Boehringer Ingelheim, MD Anderson to develop cancer drugs under research partnership
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
-
Insurtech company Oscar Health chooses MA launch markets
Oscar, which was initially founded in 2012 to serve the emerging Obamacare insurance exchanges, decided to enter into Medicare Advantage after a $375 million funding round from Alphabet last year.
-
ElevateBio names AlloVir as its first portfolio company
The Houston-based company is developing a cell therapy for viral infections in patients with compromised immune systems, which it plans to move into Phase III studies within the next 12 months. AlloVir also raised $120 million in a Series B funding round.
-
Startups, Devices & Diagnostics, Events
Pitch Perfect Winner Spotlight: CorInnova wants to change the way we treat failing hearts
Houston-based CorInnova won the medical device track for the Pitch Perfect contest at the MedCity INVEST conference in Chicago.
-
Walgreens to launch in-store primary care clinics in partnership with VillageMD
In partnership with clinic operator VillageMD, Walgreens plans to open five 2,500-square-foot in-store clinics in the Houston area by the end of the year.